
Quarterly report 2024-Q3
added 11-07-2024
Axonics Modulation Technologies Revenue 2011-2026 | AXNX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Axonics Modulation Technologies
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 274 M | 180 M | 112 M | 13.8 M | 707 K | 128 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 274 M | 128 K | 96.7 M |
Quarterly Revenue Axonics Modulation Technologies
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116 M | 115 M | 91.4 M | - | 93.1 M | 92.9 M | 70.6 M | - | 70.4 M | 69 M | 48.4 M | - | 46.9 M | 45.9 M | 34.4 M | - | 35.2 M | 15.2 M | 26.3 M | - | 1.31 M | 1.49 M | 1.08 M | - | 201 K | 12 K | - | - | 128 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 116 M | 12 K | 46.4 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aziyo Biologics
AZYO
|
24.7 M | - | 1.37 % | $ 20.5 M | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 38.77 | -1.27 % | $ 5.78 K | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Cognyte Software Ltd.
CGNT
|
443 M | $ 8.09 | 3.45 % | $ 581 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 4.1 | 2.76 % | $ 153 M | ||
|
Electromed
ELMD
|
64 M | $ 24.5 | 2.17 % | $ 207 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 9.69 | 3.09 % | $ 1.31 B | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.54 | 0.19 % | $ 122 M | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 42.93 | -1.11 % | $ 1.33 B | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
AxoGen
AXGN
|
225 M | $ 29.44 | -1.31 % | $ 1.36 B | ||
|
Apyx Medical Corporation
APYX
|
52.3 M | $ 3.26 | 2.84 % | $ 113 M | ||
|
InMode Ltd.
INMD
|
358 M | $ 13.55 | -0.37 % | $ 876 M | ||
|
IRadimed Corporation
IRMD
|
73.2 M | $ 105.35 | 1.02 % | $ 1.33 B | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
Accuray Incorporated
ARAY
|
459 M | $ 0.52 | -0.36 % | $ 53.4 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
LivaNova PLC
LIVN
|
1.39 B | $ 66.26 | -3.17 % | $ 3.61 B | ||
|
Medigus Ltd.
MDGS
|
29.9 M | - | 10.28 % | $ 55.5 M | ||
|
Pulmonx Corporation
LUNG
|
83.8 M | $ 1.47 | -3.92 % | $ 57.5 M | ||
|
Cytosorbents Corporation
CTSO
|
35.6 M | $ 0.79 | -1.75 % | $ 43 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 96.0 | -0.75 % | $ 123 B | ||
|
Align Technology
ALGN
|
4 B | $ 181.73 | -0.5 % | $ 13.6 B | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Inari Medical
NARI
|
383 M | - | - | $ 4.23 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 3.97 | 7.88 % | $ 840 M | ||
|
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | ||
|
Abbott Laboratories
ABT
|
44.3 B | $ 113.65 | 0.04 % | $ 198 B | ||
|
NuVasive
NUVA
|
1.2 B | - | - | $ 2.07 B | ||
|
Nevro Corp.
NVRO
|
409 M | - | - | $ 217 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 72.77 | -1.46 % | $ 108 B | ||
|
Orthofix Medical
OFIX
|
822 M | $ 12.98 | -0.42 % | $ 514 M |